Renal and hepatic diseases; pregnancy and lactation; GI disease; elderly, females, neonates, atopic patients. Regular monitoring of blood counts, liver and kidney functions.
Lactation: Excreted in breast milk; manufacturer suggests discontinue drug or do not nurse (AAP Committee states compatible with nursing)
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.
Mode of Action
Clindamycin inhibits protein synthesis by reversibly binding to the 50S subunit of the ribosomal thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting to stunted cell growth.
Interaction
May enhance the action of neuromuscular blocking agents (e.g. atracurium). May antagonise the effects of parasympathomimetics. May competitively inhibit the effects of macrolides, ketolides, streptogramins, linezolid and chloramphenicol. Increased coagulation tests (prothrombin time/INR) and/or bleeding w/ vit K antagonists (e.g. warfarin, acenocoumarol, fluindione).
Pregnancy Category Note
Pregnancy
In clinical trials with pregnant women, systemic administration of clindamycin during the second and third trimesters, has not been associated with increased frequency of congenital abnormalities
Clindamycin should be used during first trimester of pregnancy only if clearly needed; there are no adequate and well-controlled studies in pregnant women during first trimester of pregnancy. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed
Lactation
Clindamycin has been reported to appear in breast milk in range of 0.5 to 3.8 mcg/mL; clindamycin has potential to cause adverse effects on breastfed infant's gastrointestinal flora; if oral or intravenous clindamycin is required by nursing mother, it is not a reason to discontinue breastfeeding, but alternate drug may be preferred; monitor infant for possible adverse effects on gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in stool indicating possible antibiotic-associated colitis
The developmental and health benefits of breastfeeding should be considered along with mother's clinical need for clindamycin and any potential adverse effects on breastfed child from clindamycin or from underlying maternal condition
Adult Dose
Adult: PO Serious anaerobic infections 150-300 mg 6 hrly, up to 450 mg 6 hrly for severe infections.
Max: 1.8 g/day.
Prophylaxis of endocarditis 600 mg 1 hr before dental procedure.
IV Serious anaerobic infections 0.6-2.7 g/day in divided does, up to 4.8 g/day for severe infections.
Toxic shock syndrome W/ penicillin G or ceftriaxone: 900 mg 8 hrly.
Pelvic inflammatory disease W/ gentamicin: 900 mg 8 hrly.
Bacterial Vaginosis: 300 mg PO q12hr for 7 days
Child Dose
Neonates (less than 1 month): 15 to 20 mg/kg/day in 3 to 4 equal doses. The lower effective dosage may be adequate for small prematures.
Child: PO 10?25 mg/kg/day q8h
30?40 mg/kg/day for CA-MRSA, intra-abdominal infection, or AOM
Parenteral (IV/IM) administration: 20?40 mg/kg/day q8h. The higher doses would be used for more severe infections.
Renal Dose
N/A
Administration
Cap: May be taken with or without food. Swallow whole w/ a full glass of water & in an upright position.
Granules: Should be taken with food.
IV Preparation
Dilute 300 and 600 mg in 50 mL of D5W
Dilute 900 mg in 50-100 mL of D5W
Dilute 1200 mg in 100 mL of D5W
IV Administration
Intermittent IV infusion
Infuse over 10-60 min at a rate not exceeding 30 mg/min
300 mg doses infuse over 10 min
600 mg doses infuse over 20 min
900 mg doses infuse over 30 min
1200 mg doses infuse over 60 min; no more than 1200 mg of drug should be given by IV infusion in 1 hr
Continuous IV infusion
May give continuous IV infusion instead of intermittent after first dose has been given by rapid IV infusion
Disclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.